Supreme Court Set to Rule on Mail-Order Abortion Pill as FDA Authority Tested

TL;DR: The Supreme Court paused a lower court block on mail-order mifepristone and will decide by end of Monday whether to let the access continue. The outcome will test whether states or the FDA hold ultimate authority over the abortion drug.

After the Dobbs ruling, many states tightened abortion limits, yet medication abortions via mail rose, keeping overall US abortion numbers stable. The FDA removed the in-person dispensing requirement for mifepristone in 2023, citing safety data. Louisiana and other states now challenge that move, arguing it oversteps federal authority.

The Supreme Court’s pause, issued last week, keeps mail orders alive while the justices consider emergency requests from two manufacturers. Laurie Sobel of KFF frames the dispute as a question of who sets the floor for mifepristone regulation—states or the FDA. Nine former FDA chiefs, including Janet Woodcock and Robert Califf, contend the agency’s decision was cautious, science‑based, and consistent with its standard drug‑approval process.

The FDA’s 2023 change relied on evidence from two randomized controlled trials totaling about 1,000 participants that showed mifepristone plus misoprostol completes abortion in roughly 95% of cases. A later cohort study of over 150,000 Medicaid‑funded medication abortions found serious adverse events requiring hospitalization in less than 0.3% of patients, a rate comparable to other outpatient drugs. These data underpin the former commissioners’ argument that voluntary adverse‑event reporting, used for nearly all 20,000 FDA‑approved medicines, is sufficient.

If the Court lets the stand‑still continue, mail‑order mifepristone will remain available in states with bans, preserving a national access route despite local restrictions. Conversely, lifting the pause could empower states to enforce stricter in‑person rules, shifting regulatory power from the FDA to state legislatures and potentially triggering similar challenges to other drugs.

Watch for the Court’s decision by end of Monday and any subsequent orders that either extend the pause or remand the case to the Fifth Circuit for further review.